Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1801 results about "Kinase" patented technology

In biochemistry, a kinase is an enzyme that catalyzes the transfer of phosphate groups from high-energy, phosphate-donating molecules to specific substrates. This process is known as phosphorylation, where the substrate gains a phosphate group and the high-energy ATP molecule donates a phosphate group. This transesterification produces a phosphorylated substrate and ADP. Conversely, it is referred to as dephosphorylation when the phosphorylated substrate donates a phosphate group and ADP gains a phosphate group (producing a dephosphorylated substrate and the high energy molecule of ATP). These two processes, phosphorylation and dephosphorylation, occur four times during glycolysis. Kinases are part of the larger family of phosphotransferases. Kinases should not be confused with phosphorylases, which catalyze the addition of inorganic phosphate groups to an acceptor, nor with phosphatases, which remove phosphate groups. The phosphorylation state of a molecule, whether it be a protein, lipid, or carbohydrate, can affect its activity, reactivity, and its ability to bind other molecules. Therefore, kinases are critical in metabolism, cell signalling, protein regulation, cellular transport, secretory processes, and many other cellular pathways, which makes them very important to human physiology.

Cyclic peptide compounds and compositions as ras inhibitors

This disclosure provides cyclic peptide compounds of formula (A) or formula (II) as inhibitors of Ras kinase, and compositions and use of the same in treating diseases associated with Ras kinase.
Owner:SYNERON TECHNOLOGY CO LTD +1

Recombinant pichia pastoris strain with high astaxanthin yield as well as construction method and application of recombinant pichia pastoris strain

PendingCN120682959AFungiMicroorganism based processesPichia pastorisCholine kinase
The invention relates to a recombinant pichia pastoris strain capable of producing astaxanthin at high yield as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing ATP (adenosine triphosphate) citrate lyase (ACL) and acetyl-CoA synthase (ACS) or phosphoketolase (PK) and phosphotransacetylase (PTA), choline kinase (CK), inositol polyphosphate kinase (IPK) and vitreoscilla hemoglobin (VHB) in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-LC2. The astaxanthin production performance of the recombinant strain is verified on the basis of comparison of precursor supply pathways, IUP pathway construction and improvement of the oxygen supply capacity of the engineering strain, and the astaxanthin production capacity of the pichia pastoris is further improved. The construction method of the recombinant pichia pastoris is simple, the synthesis of astaxanthin can be better promoted, the engineering strain can efficiently synthesize the astaxanthin by utilizing methanol through amplification fermentation of a 5L fermentation tank, and industrial production is facilitated.
Owner:NANJING TECH UNIV

Talaromyces purpurogenum D2 and application thereof

The invention relates to talaromyces purpurogenus D2 and application thereof, and belongs to the technical field of microorganisms. The talaromyces purpurogenus D2 disclosed by the invention has the preservation number of GDMCC (Graphics Decific Microorganism Center) NO.66320 The strain is obtained by being separated from soil and domesticated, the zinc tolerance concentration of the strain can reach 2g / L, and the strain can efficiently convert inorganic zinc into organic active zinc which can be easily absorbed and utilized by a human body. The organic zinc prepared from the strain has a remarkable ABTS free radical scavenging capability, and also has tyrosine kinase and 5-alpha reductase inhibition capability; the organic zinc prepared from the talaromyces purpurogenum D2 can be used for preparing zinc-supplementing health-care products, can also be used as cosmetic active matter raw materials with free radical scavenging and whitening effects, and has a wide market application prospect.
Owner:GUANGZHOU AIZHUO BIOTECHNOLOGY CO LTD

Solid state forms of a kinase inhibitor

Described herein, in part, are solid-state forms of the compound represented by Formula (I), pharmaceutical compositions comprising the solid-state forms, processes of making the solid-state forms and methods of using the solid-state forms
Owner:DECIPHERA PHARMACEUTICALS LLC

Genetically engineered bacterium and application thereof in production of cis-3-hydroxy-L-proline

The invention discloses a genetically engineered bacterium and an application of the genetically engineered bacterium in production of cis-3-hydroxy-L-proline. According to the genetically engineered bacterium, a proline dehydrogenase gene putA and a proline transporter gene putP in a starting bacterium are silenced, and meanwhile, a gamma-glutamyl kinase mutant gene proBD107N, a gamma-glutamyl phosphate reductase gene proA and a cis-3-hydroxy-L-proline hydroxylase gene P3H are subjected to overexpression. And by comparing a plurality of common escherichia coli, the cis-3-hydroxy-L-proline hydroxylase gene P3H and different gamma-glutamyl kinase mutant genes, the highest yield combination is preferably selected. The strain takes glucose as a raw material, so that the production cost is greatly saved, and the strain has a relatively good industrial utilization value.
Owner:SHANGHAI SYNTHEALL PHARM CO LTD

Plasma biomarker for predicting curative effect of non-small cell lung cancer immunotherapy

PendingCN120703370AComponent separationChemiluminescene/bioluminescenceChromogranin APlasma biomarkers
The invention relates to a plasma biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the plasma biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), fibronectin 1 (FN1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and an Aly / REF output factor (ALYREF). The plasma biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

Synthesis and use of novel proteolysis chimera compound targeting interleukin-1 receptor-associated kinase 4 (IRAK4)

The present invention relates to the technical field of chemical pharmacy, and in particular to a compound for degradation of a targeted interleukin-1 receptor-associated kinase 4 (IRAK4), and a pharmaceutically acceptable salt of the compound. The compound can be used for treating or preventing IRAK4-mediated immune diseases, inflammatory diseases, and cancers.
Owner:GAN & LEE PHARM CO LTD

Method for preparing D-mannose through catalysis

The method for preparing D-mannose through catalysis can effectively reduce the amount of by-products glucose and fructose, and greatly improves the conversion rate of D-mannose. Specifically, engineering bacteria for expressing isoamylase genes and engineering bacteria for expressing alpha-glucan phosphorylase genes, glucophosphate mutase genes, difunctional enzyme glucophosphate isomerase / mannose 6-phosphate isomerase genes and mannose 6-phosphate phosphatase genes are utilized, starch or starch derivatives are used as substrates, and the starch or starch derivatives are used as substrates. A phosphate buffer solution and Mg < 2 + > are added, a preliminary catalysis system is constructed, after the reaction is completed, an incompletely-reacted substrate and maltodisaccharide exist in the reaction system, the incompletely-reacted substrate and maltodisaccharide can be hydrolyzed into glucose by glucoamylase, and the polyphosphoglucokinase can be used for catalyzing the reaction of the polyphosphoglucokinase under the assistance of sodium hexametaphosphate. All glucose is converted into phosphorylated glucose, then D-mannose is generated, and by-products in a system are removed while the yield is increased.
Owner:BINZHOU SANYUAN BIOLOGICAL TECH

Tropomyosin receptor kinase (TRK) degradation compounds and methods of use

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.
Owner:CULLGEN (SHANGHAI) INC

Engineered DXP pathway for improved isoprenoid production in e. coli

PCT designated stage expiredWO2025155822A1Phosphorus-oxygen lyasesTransferasesHeterologousIsomerase
The present disclosure relates to recombinant microorganisms, such as bacteria, e.g., E. coli, engineered to have improved flux and / or yield of the DXP pathway. Cells can be engineered to comprise nucleotide sequences comprising dxs polypeptides (EC 2.2.1.7); dxr polypeptides (EC 1.1.1.267); ispD polypeptides (EC 2.7.7.60); ispE polypeptides (EC 2.7.1.148); ispF polypeptides (EC 4.6.1.12); ispG polypeptides (EC 1.17.7.1 or EC 1.17.7.3); ispH polypeptides (EC 1.17.7.4); and idi polypeptides (EC 5.3.3.2). Cells can be further engineered to express redox polypeptides, e.g., ferredoxins, flavodoxins, and / or flavodoxin / ferredoxin--NADP reductases (EC 1.19.1.1 or EC 1.18.1.2), e.g., to increase the activity of the ispG and / or ispH polypeptides. Some or all of the nucleotide sequences can be heterologous to the cells. The recombinant microorganisms can be used in methods of isoprenoid production.
Owner:BP CORP NORTH AMERICA INC

High-thermal-stability deoxyadenosine kinase mutant and application thereof

PendingCN120210152ABacteriaTransferasesDeoxyadenosine monophosphateReaction temperature
The invention provides a high-thermal-stability deoxyadenosine kinase mutant and application thereof, and belongs to the field of enzyme engineering. Compared with an amino acid sequence as shown in SEQ ID NO.1, the high-thermal-stability deoxyadenosine kinase mutant provided by the invention has mutation of at least one amino acid site, and the mutation comprises V40G, D121T and S154L. In the high-thermal-stability deoxyadenosine kinase mutant provided by the invention, the half-life period of V40G at 50 DEG C is 1.02 h, the half-life period of D121T at 50 DEG C is 9.51 h, and the half-life period of S154L at 50 DEG C is 5.23 h, which are significantly higher than those of a wild type. The high-thermal-stability deoxyadenosine kinase provided by the invention can be used for enzymatic preparation of 2 '-deoxyadenosine monophosphate, deoxyadenosine and deoxyadenosine triphosphate react to obtain deoxyadenosine monophosphate by adopting a one-pot enzymatic method, and the high-thermal-stability deoxyadenosine kinase is simple to operate, can tolerate higher reaction temperature and has the advantage of industrial amplification.
Owner:HANGZHOU MEIYA PHARM CO LTD

Recombinant pichia pastoris strain with high yield of retinaldehyde as well as construction method and application of recombinant pichia pastoris strain

The invention discloses a recombinant pichia pastoris strain with high yield of retinaldehyde as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing dehydrogenase Zwf1, phosphate dehydrogenase Gnd2, NADH kinase Pos5 and two copied beta-carotene-15, 15 '-monooxygenase BCMO in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-B (Propene Polymer-B). The retinaldehyde production performance of the recombinant strain is verified based on cofactor engineering and the copy number of key enzymes, and the retinaldehyde production capacity of the pichia pastoris is further improved. The recombinant pichia pastoris disclosed by the invention is simple in construction method, can better promote the synthesis of retinol, and is beneficial to industrial production as the engineering strain can efficiently synthesize retinol by using methanol as a unique carbon source through amplification fermentation in a 5L fermentation tank.
Owner:NANJING TECH UNIV

Novel deuterated JAK2 inhibitor as well as preparation method and application thereof

The invention belongs to the technical field of biological medicine, and particularly relates to a novel deuterated JAK2 inhibitor or pharmaceutically acceptable salt thereof. Compared with the prior art, the compound or the pharmaceutically acceptable salt thereof provided by the invention has better JAK2 inhibition activity, and the JAK2 inhibition target selectivity of the compound or the pharmaceutically acceptable salt thereof is obviously superior to that of the existing compound, so that the compound or the pharmaceutically acceptable salt thereof has better druggability.
Owner:HC SYNTHETIC PHARMA CO LTD

Bioengineering bacteria for full fermentation of stevioside and application of bioengineering bacteria

The invention belongs to the technical field of biosynthesis, and particularly relates to an engineering bacterium for preparing stevioside through de novo fermentation as well as a preparation method and application of the engineering bacterium. According to the invention, mevalonate kinase in the MVA pathway is mutated and optimized. The method comprises the following steps: carrying out point mutation on mevalonate kinase MvK of a wild type source, constructing a stevioside synthesis route in an escherichia coli host, and comparing the influence of MvK mutation on the yield of stevioside, so as to determine a Q160L mutant, and applying the Q160L mutant to the stevioside production route to realize efficient production of stevioside.
Owner:SICHUAN INGIA BIOSYNTHETIC CO LTD

Valine production strain as well as construction method and application thereof

The invention provides a valine production strain and a construction method and application thereof, a designed acetohydroxy acid synthase mutant is that the 88th basic group of an ilvB gene is changed from a to c, the 382nd basic group is changed from a to g, the 413th basic group is changed from c to t, the gene sequence of a designed artificial operon comprises a promoter, an ilvB (A138V) gene or ilvB (Q30K, S128G, A138V) gene of coding mutated acetohydroxy acid synthase, and an ilvN (G20D, I21D, I21D, I21D, I21D, I21D, I21D, I21D) gene. I22F) gene, a pyk gene for coding pyruvate kinase, and a terminator; by designing a specific acetohydroxyacid synthase mutant and related biological materials and artificial operon, the strain constructed by directional modification of the strain by using a pK18mobsacB system gene editing technology based on allele exchange has the advantages of good genetic stability, high fermentation yield and the like, and valine can be stably produced.
Owner:TIANJIN HERUN BIOTECHNOLOGY CO LTD

Recombinant yeast cell

PendingUS20250283121A1TransferasesBiofuelsYeastDihydroxyacetone kinase
A recombinant yeast cell that functionally expresses: —a nucleic acid sequence encoding a protein having glycerol dehydrogenase activity; —a nucleic acid sequence encoding a protein having dihydroxyacetone kinase activity; and —a nucleic acid sequence encoding a protein having glycerol transporter activity, wherein the expression of the nucleic acid sequence encoding the protein having glycerol transporter activity is under control of a promoter (the “GT promoter”), which GT promoter has an anaerobic / aerobic expression ratio for the glycerol transporter of 2 or more, and a process for the production of ethanol using such recombinant yeast cell.
Owner:DANISCO US INC

Novel polypeptide capable of regulating activity of AMPK (adenosine monophosphate kinase) and pharmaceutical application of novel polypeptide

The invention relates to the technical field of biological medicine, in particular to a novel polypeptide and application thereof in medicine for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence, and is composed of an amino acid sequence of SEQ. NO: 1: Leu-Asn-Pro-Thr-Glu (LNPTG), an amino acid sequence of SEQ. NO: 2: Val-His-Met-Arg-Tyr (VHMRY), and the like. The polypeptide has a unique amino acid sequence, and provides a new way for the treatment of cardiovascular diseases by adjusting the activity of AMPK and improving the cardiovascular function.
Owner:ZHEJIANG GUOBEN PHARM GRP CO LTD

Rice receptor-like kinase OsLTK1 and application thereof in resistance of magnaporthe oryzae

The invention belongs to the technical field of biology, and discloses a rice receptor-like kinase OsLTK1 and application thereof in resistance of magnaporthe oryzae. It is found for the first time that receptor-like kinase OsLTK1 positively regulates the resistance of rice to magnaporthe oryzae. The research shows that the transgenic plant of the OsLTK1 gene overexpressed in the rice has obvious resistance to the magnaporthe oryzae. Therefore, the OsLTK1 gene can be used for cultivating rice blast resistant rice varieties, and has great application value.
Owner:SANYA INSTITUTE OF NANJING AGRICULTURAL UNIVERSITY

Genetically engineered bacterium for producing bacterial cellulose as well as construction method and application of genetically engineered bacterium

PendingCN120399999ABacteriaTransferasesGlycerol kinaseEngineered genetic
The invention provides a genetically engineered bacterium for producing bacterial cellulose as well as a construction method and application of the genetically engineered bacterium, and belongs to the technical field of bioengineering. According to the invention, a K.medellensis expression vector is constructed, a glycerol transporter expression vector and a glycerol kinase expression vector are further constructed based on the K.medellensis expression vector, and the K.medellensis glycerol transporter expression vector and the glycerol kinase expression vector are transformed into K.medellensis to construct a genetically engineered bacterium for producing bacterial cellulose; glycerin and corn steep liquor are directly used as a carbon source and a nitrogen source respectively, and the fermentation conditions of the genetically engineered bacteria are further optimized, so that environment-friendly and low-cost synthesis of the bacterial cellulose is realized, the yield of the bacterial cellulose is remarkably increased, and the method has good practicability.
Owner:GUANGZHOU UNIVERSITY

A pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications

The present application relates to a pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications, and belongs to the technical field of biological catalysis. In order to solve the problem of low product concentration in existing enzyme catalysis, a pyridoxal kinase mutant is provided, the amino acid sequence is selected from the amino acid sequence shown in SEQ ID NO. 1, the lysine at position 229 is mutated to alanine, phenylalanine, methionine, arginine, threonine, histidine, serine, tyrosine, valine, leucine, isoleucine, proline, asparagine, aspartic acid or glutamic acid; the pyridoxal kinase mutant is used for catalyzing pyridoxal to synthesize pyridoxal phosphate, and a recombinant expression vector and a microbial cell can be further formed. The present application has good enzyme activity, high product conversion rate, high concentration of pyridoxal phosphate obtained, and the concentration of the product catalyzed by the wild-type pyridoxal kinase to phosphorylate pyridoxal is obviously improved.
Owner:TAIZHOU LINGFENG BIOTECHNOLOGY CO LTD

Escherichia coli recombinant engineering bacterium for producing citicoline as well as construction method and application of escherichia coli recombinant engineering bacterium

ActiveCN120192906ABacteriaAntibody mimetics/scaffoldsEscherichia coliCytidine Diphosphate Choline
The invention discloses escherichia coli recombinant engineering bacteria for producing citicoline as well as a construction method and application of the escherichia coli recombinant engineering bacteria, and belongs to the technical field of biology. A genome cytidine deaminase coding gene cdd is knocked out on the basis of Escherichia coli K-12 MG1655, a temperature control expression vector PBV220 is used for expressing a SpnCCT-SpnCKI-pRpLpyrG mutant gene cluster, the expression of choline transporter protein BetT is enhanced, the gene locus of Escherichia coli ptsH-ptsI-crr is destroyed, meanwhile, a glucose permease gene glf and a glucokinase gene glk from Zymomonas mobilis are introduced, and the mutant gene cluster of the Escherichia coli K-12 MG1655 is obtained. The escherichia coli recombinant engineering bacterium ZMCB02NCL capable of efficiently biosynthesizing citicoline is obtained, and the preservation number of the escherichia coli recombinant engineering bacterium ZMCB02NCL is CCTCC NO: M 2025483.
Owner:GUANGDONG ZHUMEI BIOMEDICAL TECH CO LTD

Inhibitors of kinase networks and uses thereof

ActiveUS12384782B2Organic chemistry methodsHistone demethylationPharmaceutical drug
The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and / or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.
Owner:PURDUE RES FOUND

Method for biological high-density synthesis of retinaldehyde and synthetic strain thereof

PendingCN121006286AFungiTransferasesCholine kinaseRetinoid
The invention discloses a method for biological high-density synthesis of retinaldehyde and a synthetic strain thereof. The synthetic strain is obtained by expressing ATP citrate lyase ACL, acetyl-CoA synthase ACS, choline kinase CK, inositol polyphosphate kinase IPK and vitreoscilla hemoglobin VHb in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified bacterial strain PP-B2C. The retinaldehyde production performance of the recombinant strain is verified on the basis of a precursor supply pathway, an IUP pathway and a dissolved oxygen level, and the retinaldehyde production capacity of the pichia pastoris is further improved. The construction method of the recombinant pichia pastoris is simple, the synthesis of retinaldehyde can be better promoted, and the retinaldehyde can be efficiently synthesized by the engineering strain by utilizing glucose and methanol through amplification fermentation of a 5L fermentation tank, so that the recombinant pichia pastoris is beneficial to industrial production.
Owner:NANJING TECH UNIV

Pharmaceutical composition comprising PRMT5 inhibitor and EGFR inhibitor

Disclosed is a pharmaceutical composition, comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor. The pharmaceutical composition can be used to treat various cancers, including solid tumors. The combination product can be used to treat any number of diseases associated with PRMT5 and / or EGFR.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

Recombinant yeast cell

PendingUS20250320529A1FungiBiofuelsYeastAcetate kinase activity
A recombinant yeast cell functionally expressing: a) a nucleic acid sequence encoding a protein comprising phospho-ketolase (PKL) activity (EC 4.1.2.9 or EC 4.1.2.22) and / or a nucleic acid sequence encoding a protein having phosphotransacetylase (PTA) activity (EC 2.3.1.8) and / or a nucleic acid sequence encoding a protein having acetate kinase (ACK) activity (EC 2.7.2.12); and / or) a nucleic acid sequence encoding a protein having transketolase activity (EC 2.2.1.1), wherein the expression of the nucleic acid sequence encoding the protein having transketolase activity is under control of a promoter (the “TKL promoter”), which TKL promoter has an anaerobic / aerobic expression ratio for the transketolase of (2) or more.
Owner:DANISCO US INC

ROCK2 inhibitors for treatment of viral infections

The present disclosure provides compositions and methods comprising a selective inhibitor of Rho-related coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae caused by the viral infections, including sequelae caused by coronavirus infections.
Owner:GRAVITON BIOSCIENCE BV

Beta-alanine producing strain as well as construction method and application thereof

InactiveCN120888478ABacteriaAntibody mimetics/scaffoldsPhosphoenolpyruvate carboxylasePantothenic acid
The invention provides a beta-alanine producing strain as well as a construction method and application thereof. According to the bacterial strain, an acetaldehyde dehydrogenase gene adhE, a lactic dehydrogenase gene ldhA, an acetokinase gene ackA, a pyruvate dehydrogenase gene poxB, a DNA binding transcription inhibition factor coding gene lacI, an aspartate kinase thrA, a pantothenic acid synthase gene panC, an alanine synthesis transaminase gene cycA and an alanine synthesis transaminase gene yfbQ are knocked out from an E.coli W3110 genome, and the bacterial strain is obtained. A phosphoenolpyruvate carboxylase gene ppc, a pyridine nucleotide transhydrogenase coding gene pntAB, an aspartic acid transaminase gene aspC, an aspartic acid decarboxylase gene panD derived from pseudomonas aeruginosa and a beta-alanine transporter gene NCgl0580 derived from corynebacterium glutamicum are integrated at the same time, and the bacillus subtilis is used for producing beta-alanine and has the advantage of high fermentation yield.
Owner:TIANJIN UNIV OF SCI & TECH